How do you pay?

How to pay the least

Ask for the cash price

Nubeqa

We didn’t find one.

  1. Ask your pharmacy for Nubeqa’s cash price, and one or two other pharmacies too.
  2. Nubeqa’s savings card works only with insurance from a job or one you bought.

Free from the maker, if you qualify Bayer US Patient Assistance Foundation. Effective January 1, 2025, the financial eligibility requirement is 300% Federal Poverty Limit (FPL) for most Bayer prescription medications. Or call 1-866-228-7723.

See if you qualify 

Compare every option

Question
Brand nameNubeqa
Authorized genericdarolutamide
Regular genericdarolutamide
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Nubeqa?
The original
–
–

Brand nameThe maker’s card

NUBEQA $0 Co-Pay Program

Savings card from Bayer

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a fill

The card takes up to $25,000 a year off your co-pay.

Sign up on nubeqa-us.com 

In the maker’s words

“Eligible patients may pay as little as $0 and save up to $25,000 per year.”

From the maker’s offer on nubeqa-us.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Nubeqa itself, from the same company, sold without the brand name, and usually for less. For now Nubeqa is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

NUBEQA is an androgen receptor inhibitor indicated for the treatment of adult patients with:

  • non-metastatic castration-resistant prostate cancer (nmCRPC).
  • metastatic castration-sensitive prostate cancer (mCSPC).
  • metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel.

Source: the FDA label for Nubeqa (Bayer HealthCare Pharmaceuticals Inc.), September 28, 2026. Full label on DailyMed 

Good to know